ClinicalTrials.gov
ClinicalTrials.gov Menu

CIMAvax Vaccine and Anti-PD1 Therapy in Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02955290
Recruitment Status : Recruiting
First Posted : November 4, 2016
Last Update Posted : January 11, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute

November 2, 2016
November 4, 2016
January 11, 2019
December 9, 2016
June 9, 2020   (Final data collection date for primary outcome measure)
  • DLT as graded by CTCAE v. 4.03 (Phase I) [ Time Frame: Up to 4 weeks (2 doses of study drugs) ]
    No formal analyses of DLTs are planned. Presentation of DLTs will be limited to DLT-evaluable patients.
  • Overall survival (Phase II) [ Time Frame: At 12 months ]
    Overall survival will be presented using Kaplan-Meier plots and associated statistics.
  • Percentage of patients with high antibody titers defined as >= 1:4000 (Phase I) [ Time Frame: At 12 months ]
    The percentage of patients with antibody titers >= 1:4000 at 12 months will be presented by treatment schedule and by time point (0, 3, 6, 9, and 12 months). In addition, a mixed effects model will be used to analyze and compare treatment schedules across time. Antibody titers may be transformed (e.g., log) as appropriate.
  • DLT as graded by CTCAE v. 4.03 (Phase I) [ Time Frame: Up to 4 weeks (2 doses of study drugs) ]
    No formal analyses of DLTs are planned. Presentation of DLTs will be limited to DLT-evaluable patients.
  • Overall survival (Phase II) [ Time Frame: At 12 months ]
    Overall survival will be presented using Kaplan-Meier plots and associated statistics.
  • Percentage of patients with high antibody titers defined as >= 1:4000 (Phase I) [ Time Frame: Up to 12 months from 5th vaccine dose ]
    The percentage of patients with antibody titers >= 1:4000 at 12 months will be presented by treatment schedule and by time point (0, 3, 6, 9, and 12 months). In addition, a mixed effects model will be used to analyze and compare treatment schedules across time. Antibody titers may be transformed (e.g., log) as appropriate.
Complete list of historical versions of study NCT02955290 on ClinicalTrials.gov Archive Site
  • Incidence of adverse events (AEs) graded according to NCI CTCAE v4.03 (Phase I and II) [ Time Frame: Up to 30 days after the last dose of study treatment ]
    The maximum grade for each type of AEs will be recorded for each patient based on NCI CTCAE version 4.0. The frequency of AEs will be tabulated by maximum grade per event across all dose levels and cycles. All patients who receive any study treatment will be considered evaluable for toxicity.
  • PFS based on irRECIST (Phase II) [ Time Frame: Up to 12 months ]
    PFS will be presented using Kaplan-Meier plots and associated statistics.
  • EGFR and PD-1 expression and mutations in tumor tissue (Phase I and II) [ Time Frame: Up to 14 days after the last dose of CIMAvax ]
    EGFR and PD-1 expression and mutations in tumor tissue will be reported using appropriate descriptive statistics. The association between these measures and the biomarkers of immune response will be evaluated using general linear models.
  • Incidence of adverse events (AEs) graded according to NCI CTCAE v4.03 (Phase I and II) [ Time Frame: Up to 30 days after the last dose of study treatment ]
    The maximum grade for each type of AEs will be recorded for each patient based on NCI CTCAE version 4.0. The frequency of AEs will be tabulated by maximum grade per event across all dose levels and cycles. All patients who receive any study treatment will be considered evaluable for toxicity.
  • PFS based on irRECIST (Phase II) [ Time Frame: Up to 12 months ]
    PFS will be presented using Kaplan-Meier plots and associated statistics.
  • Serum EGF levels, platelet levels, markers of immune response, and antibody functionality (Phase I and II) [ Time Frame: Up to 12 months from 5th vaccine dose ]
    Serum EGF levels, platelet levels, and biomarkers of immune response will be reported using appropriate descriptive statistics. Associations between these measures will be explored in the overall sample using the correlation coefficients.
  • Blood EGF levels, platelet levels, markers of immune response, and antibody functionality (Phase I and II) [ Time Frame: Up to 12 months from 5th vaccine dose ]
    Blood EGF levels, platelet levels, and biomarkers of immune response will be reported using appropriate descriptive statistics. Associations between these measures will be explored in the overall sample using the correlation coefficients.
  • EGFR and PD-1 expression and mutations in tumor tissue (Phase I and II) [ Time Frame: Up to 14 days after the last dose of CIMAvax ]
    EGFR and PD-1 expression and mutations in tumor tissue will be reported using appropriate descriptive statistics. The association between these measures and the biomarkers of immune response will be evaluated using general linear models.
  • Response assessed using irRECIST, irRC, and RECIST 1.1 (Phase I and II) [ Time Frame: Up to 12 months ]
    Response assessment criteria will be compared between irRECIST, irRC, and RECIST 1.1 for a prospective analysis.
Not Provided
 
CIMAvax Vaccine and Anti-PD1 Therapy in Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
A Phase I/II Basket Trial of the EGF Vaccine CIMAvax in Combination With Anti-PD1 Therapy in Patients With Advanced NSCLC or Squamous Head and Neck Cancer
This phase I/II trial studies the best dose and side effects of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and nivolumab and to see how well they work in treating patients with non-small cell lung cancer or squamous head and neck cancer that has spread to other places in the body. Vaccine therapy, such as CIMAvax vaccine may help slow down and stop tumor growth. Immunotherapy with monoclonal antibodies, such as nivolumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CIMAvax vaccine together with nivolumab or pembrolizumab may work better in treating patients with non-small cell lung cancer or squamous head and neck cancer.

PRIMARY OBJECTIVES:

  • To identify the maximum dose of CIMAvax in combination with nivolumab based on dose limiting toxicities (DLTs) as assessed by Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03). (Phase I)
  • To evaluate the 12-month overall survival of CIMAvax combined with nivolumab in patients with advanced NSCLC. (Phase II Study A)
  • To evaluate the 6-month PFS of CIMAvax combined with nivolumab in patients with advanced recurrent squamous cell carcinoma of the head and neck. (Phase II, Study B)
  • To evaluate the objective response rate of pembrolizumab in combination with CIMAvax as first-line therapy in patients with advanced NSCLC (PD-L1 expression ≥ 50%). (Phase II, Study C)

SECONDARY OBJECTIVES

  • To assess the toxicity of CIMAvax combined with nivolumab using the Cancer Therapy Evaluation Program (CTEP) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE version 4.03). (Phase I)
  • Determine the preliminary efficacy of the combination of anti-PD1 therapy with CIMAvax. (Phase I)
  • To evaluate progression free survival (PFS) for the combination of CIMAvax and nivolumab in patients with advanced NSCLC. If the results of Phase II Study A are promising, an expansion cohort may be opened to determine the longest period between CIMAvax doses that maintains an optimal response titer in the maintenance therapy setting.(Phase II Study A)
  • To evaluate the 12-month overall survival of patients with advanced recurrent squamous cell carcinoma of the head and neck who received Nivolumab in combination with CIMAvax. Phase II, Study B)
  • To evaluate the PFS and 12-month overall survival of CIMAvax in combination with pembrolizumab as first-line therapy in patients with advanced NSCLC (PD-L1 expression ≥ 50%). (Phase II, Study C)
  • To assess the toxicity of CIMAvax combined with nivolumab using the CTEP NCI Common Terminology Criteria for Adverse Events (CTCAE version 4.03). (Phase II)

TERTIARY OBJECTIVES:

  • To conduct correlative studies comparing blood EGF levels, platelet levels, markers of immune response and functionality of antibody response. (Phase I)
  • To examine the association of EGFR (total and activated), PD-1 and PD-L1 expression and mutations in tumor tissue with biomarkers of genetic and immune response. (Phase I and II)
  • Comparison of response assessment criteria for a prospective analysis (irRECIST response assessment versus [vs.] immune-related Response Criteria [irRC] vs. RECIST 1.1). (Phase I and II)
  • To characterize the blood EGF levels and other blood-based biomarkers of patients censored from the trial because of low titer response. (Phase II)

OUTLINE: This is a phase I dose escalation study of CIMAvax followed by a phase II study.

LOADING PHASE I: Patients receive CIMAvax intramuscularly (IM) and nivolumab intravenously (IV) over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 doses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax IM at the same time as the next nivolumab dose.

MAINTENANCE PHASE I: Patients who do not experience a DLT receive CIMAvax every 4 weeks and nivolumab every 2 weeks.

PHASE II STUDY A and B: Patients receive CIMAvax intramuscularly (IM) and nivolumab intravenously (IV) over 60 minutes. Courses for nivolumab repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients in Study A with antibody titer >= 1:4000 at the end of the loading phase may receive CIMAvax IM every 8 or 12 weeks during the maintenance phase.

PHASE II STUDY C: Patients with PD-L1expression >= 50% receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for pembrolizumab repeat every 2 weeks for 2 years in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 30 days for 120 days.

Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • ALK Gene Mutation
  • EGFR Gene Mutation
  • Recurrent Non-Small Cell Lung Carcinoma
  • Stage IIIB Non-Small Cell Lung Cancer
  • Stage IV Non-Small Cell Lung Cancer
  • Other: Laboratory Biomarker Analysis
    Correlative studies
  • Biological: Nivolumab
    Given IV
    Other Names:
    • BMS-936558
    • MDX-1106
    • NIVO
    • ONO-4538
    • Opdivo
  • Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
    Given CIMAvax IM
    Other Names:
    • Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine
    • Center of Molecular Immunology Epidermal Growth Factor Vaccine
    • CimaVax
    • CIMAvax EGF
    • CIMAvax Epidermal Growth Factor Vaccine
    • CIMAvax-EGF
    • Recombinant Human EGF-P64K/Montanide Vaccine
  • Experimental: Phase I (CIMAvax, nivolumab)

    LOADING PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks up to 4 doses in the absence of disease progression or unacceptable toxicity. Within 4 weeks after the 4th dose, patients receive CIMAvax and nivolumab every 2 weeks..

    MAINTENANCE PHASE I: Patients receive CIMAvax IM and nivolumab IV over 60 minutes. Courses repeat every 4 weeks for CIMAvax and every 2 weeks for nivolumab in the absence of disease progression or unacceptable toxicity.

    Interventions:
    • Other: Laboratory Biomarker Analysis
    • Biological: Nivolumab
    • Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
  • Experimental: Phase II Study A and B (CIMAvax, nivolumab)

    PHASE II Study A and B: Patients receive CIMAvax IM and nivolumab IV over 60 minutes . Treatment with CIMIVax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for nivolumab repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients in Study A with antibody titer >= 1:4000 at the end of the loading phase may receive CIMAvax IM every 8 or 12 weeks during the maintenance phase.

    Interventions:
    • Other: Laboratory Biomarker Analysis
    • Biological: Nivolumab
    • Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
  • Experimental: Phase II Study C (CIMAvax, pembrolizumab)
    PHASE II Study C: Patients with PD-L1 expression >= 50% receive CIMAvax IM and pembrolizumab IV over 30 minutes. Treatment with CIMAvax repeats every 2 weeks for 4 doses during the loading phase and every 4 weeks during the maintenance phase in the absence of disease progression or unacceptable toxicity. Courses for pembrolizumab repeat every 2 weeks for 2 years in the absence of disease progression or unacceptable toxicity. .
    Interventions:
    • Other: Laboratory Biomarker Analysis
    • Biological: Nivolumab
    • Biological: Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
136
Same as current
June 9, 2021
June 9, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 at the time of study treatment initiation
  • Have pathologically confirmed diagnosis of NSCLC (Phase 1, Phase II Studies A, C and Expansion Cohort AE) or Squamous cell head and neck Cancer (Phase II Study B).
  • Must be eligible for treatment with nivolumab as standard of care (for nivolumab treatment groups only).
  • Phase II Study A and Expansion Cohort AE: Patients with advanced (metastatic) NSCLC, whose disease progressed during or after platinum based therapy.
  • Phase II Study B: Patients with advanced recurrent head and neck squamous cell carcinoma.
  • Phase II Study C: Patients with advanced unresectable NSCLC, first-line therapy with PD-L1 expression ≥ 50%. In the rare event that there is a discrepancy in the results of PD-L1 testing (i.e. 2 or more specimens were tested, etc.), eligibility status will be per the discretion of the PI after review of other available biomarker testing.
  • NSCLC patients in study A and expansion cohort AE with EGFR or ALK genomic tumor aberrations (determined through either tissue- or liquid biopsy-based platform) should have disease progression on FDA approved therapy for these aberrations prior to receiving anti-PD1 therapy. Patients with smoking history being considered for Study C may enroll and be treated pending results of molecular testing
  • Have at least 6 month life expectancy
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
  • Platelets >= 100 x 10^9/L
  • Hemoglobin >= 9 g/dL
  • Serum creatinine =< 1.5 x institution upper limit of normal (ULN) or estimated GFR (measured or calculated with Cockroft and Gault formula) > 45/m1/min
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (ALT and AST =< 5 x ULN is acceptable if liver metastases are present)
  • Total serum bilirubin =< 1.5 x ULN; for patients with well documented Gilbert's syndrome, total bilirubin =< 3 x ULN with direct bilirubin within normal range
  • Troponin-I, creatine kinase muscle and brain (CK-MB), =< ULN,B-type natriuretic peptide (BNP) <200pg/mL
  • Left ventricular ejection fraction (LVEF) >= LLN (institutional limit)
  • Patients enrolled onto Phase I dose escalation or Expansion Cohort (AE) must have presence of evaluable disease. Patients enrolled onto Phase II studies A, B or C must have measurable disease as defined in RECIST 1.
  • Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure
  • Phase II only: participant agrees to provide tumor biopsy tissue before treatment, blood samples at the start of treatment and at multiple times during the study and, a tumor biopsy at the end of the trial or after disease progression. Archival FFPE tissue is permitted for Expansion Cohort AE. Archival FFPE tissue is also permitted for Study C patients provided that tissue is adequate and no systemic anti-cancer therapy had been administered between the time specimen was obtained and start of protocol therapy.

Exclusion Criteria:

  • Receipt of anticancer chemotherapy within 4 weeks before the first administration of study drug
  • Previous anti-PD1 or PDL1 immunotherapy is not allowed. Treatment with other investigational agents within 6 half-lives of first administration of study drug is not allowed
  • Any patients requiring 24-hour continuous oxygen therapy
  • Prior radiotherapy or gamma knife within 2 weeks of study treatment; subjects must have recovered from all radiation related toxicities
  • Active/untreated brain metastasis; whole brain radiation or gamma knife radiosurgery performed less than 4 weeks prior to first administration of study drug; previously treated brain metastasis allowed as long as not requiring steroids and stable on imaging at least 4 weeks after completing radiation therapy
  • Leptomeningeal involvement regardless of treatment status
  • Tumor with mutation that is known to be sensitive to FDA approved targeted therapy but has not yet received such targeted therapy
  • History of autoimmune disorder, with exception of patients with vitiligo or endocrine- related autoimmune conditions receiving appropriate hormonal supplementation who are eligible; Systemic use of immunosuppressant drugs such as steroids (except as hormone replacement therapy or short-course supportive medication such as chemotherapy or drug allergy, etc.), azathioprine, tacrolimus, cyclosporine, etc.; within 4 weeks before recruitment
  • Currently receiving or has received systemic corticosteroids within 4 weeks prior to starting study drug for management of brain metastases, or who have not fully recovered from side effects of such treatment (steroids for endocrine replacement or receipt of short-course of steroids during this preceding 4 week period as supportive medication such as for drug allergy, anti-emetic, etc. is allowed)
  • Had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery
  • Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired immune deficiency syndrome [AIDS] or other immune depressing disease); testing is not mandatory
  • Active, clinically serious infections or other serious uncontrolled medical conditions
  • Patient has known hypersensitivity to the components of the study drugs or any analogs
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating investigator, including, but not limited to:

    • Myocardial infarction or arterial or venous thromboembolic events within 6 months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) class III or IV disease
    • History of documented congestive heart failure (New York Heart Association functional classification III or IV)
    • Documented history of cardiomyopathy.
    • Uncontrolled hypertension (systolic blood pressure [SBP] > 160/diastolic blood pressure [DBP] > 100 despite medical intervention)
    • History of myocarditis of any etiology
    • History of cardiac surgery
    • History of ventricular arrhythmias
  • Phase II only : Patients diagnosed with an invasive cancer within 2 years prior to starting protocol therapy with the following exceptions: non-melanoma skin cancers, in-situ cancers, and prostate cancer Gleason =< to 6 (under surveillance or treated), early stage node-negative ER+/PR+breast cancer with Oncotype Dx score <25 not taking adjuvant hormonal therapy
  • Pregnant or nursing female participants
  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug
  • Unwilling or unable to follow protocol requirements
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
United States
 
 
NCT02955290
I 286816
NCI-2016-01467 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
I 286816 ( Other Identifier: Roswell Park Cancer Institute )
P30CA016056 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
Roswell Park Cancer Institute
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Principal Investigator: Grace Dy Roswell Park Cancer Institute
Roswell Park Cancer Institute
January 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP